Longhorn Vaccines & Diagnostics and Pharmco have combined to rapidly accelerate coronavirus testing and detection which are critical to combating the global COVID-19 pandemic.
Unlike standard methods for collecting and transporting samples, Longhorn's PrimeStore MTM® safely deactivates pathogens at the point of collection and stabilizes RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory-based molecular testing and characterization with no need for special containment facilities.
"Safe and robust collection of high-quality samples that can be processed on standard lab benches using conventional qPCR have enabled rapid detection from patients and assisted in combating the global COVID19 pandemic," said Dr. Luke T. Daum, Chief Scientific Officer at Longhorn Vaccines and Diagnostics and the inventor of PrimeStore MTM®. "What makes PrimeStore MTM® so important is that once an oral or nasal swab is collected, the viruses and bacteria from the sample are lysed/inactivated, the RNA and DNA are stabilized for safe transport and processing outside of BSL-2/3 laboratories."
"Formulating solvents that meet our customers' criteria allows us to help them make incredible products and meet the demands of the market," said Steve DiBenedetto, Senior Vice President of Sales & Operations. "Our Pharmco branded products are blended and packaged at our GMP-compliant facilities operating under an ISO 9001:2015 Quality Management System which ensures a high quality, consistent product. Longhorn Vaccines and Diagnostic Testing's innovation is remarkable. We value their trust in our top-quality products, our security of supply, and our reliable supply chain, which allows us to help support millions of critical tests worldwide." PrimeStore MTM® is an FDA-cleared collection medium for respiratory samples, including SARS-CoV-2 virus and has emerged to become a critical tool in the fight against COVID19.